110 related articles for article (PubMed ID: 22740622)
1. von Willebrand factor antigen--a possible biomarker of disease activity in childhood central nervous system vasculitis?
Cellucci T; Tyrrell PN; Pullenayegum E; Benseler SM
Rheumatology (Oxford); 2012 Oct; 51(10):1838-45. PubMed ID: 22740622
[TBL] [Abstract][Full Text] [Related]
2. Childhood primary angiitis of the central nervous system: identifying disease trajectories and early risk factors for persistently higher disease activity.
Cellucci T; Tyrrell PN; Sheikh S; Benseler SM
Arthritis Rheum; 2012 May; 64(5):1665-72. PubMed ID: 22544528
[TBL] [Abstract][Full Text] [Related]
3. Primary central nervous system vasculitis in children.
Benseler SM; Silverman E; Aviv RI; Schneider R; Armstrong D; Tyrrell PN; deVeber G
Arthritis Rheum; 2006 Apr; 54(4):1291-7. PubMed ID: 16575852
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system vasculitis in children.
Cellucci T; Benseler SM
Curr Opin Rheumatol; 2010 Sep; 22(5):590-7. PubMed ID: 20671523
[TBL] [Abstract][Full Text] [Related]
5. Childhood central nervous system vasculitis.
Benseler S; Pohl D
Handb Clin Neurol; 2013; 112():1065-78. PubMed ID: 23622312
[TBL] [Abstract][Full Text] [Related]
6. Childhood primary angiitis of the central nervous system.
Malik MA; Zia-ur-Rehman M; Nadeem MM; Chaudhry FR; Qureshi AA; Nawaz M; Malik H
J Coll Physicians Surg Pak; 2012 Sep; 22(9):570-4. PubMed ID: 22980610
[TBL] [Abstract][Full Text] [Related]
7. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
[TBL] [Abstract][Full Text] [Related]
8. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy.
Martínez-Dolz L; Almenar L; Reganon E; Vila V; Chamorro C; Andrés L; Martínez-Sales V; Moro J; Agüero J; Sánchez-Lázaro I; Salvador A
J Heart Lung Transplant; 2008 Jul; 27(7):760-6. PubMed ID: 18582806
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: potential markers for disease activity.
D'Cruz D; Direskeneli H; Khamashta M; Hughes GR
J Rheumatol; 1999 Jan; 26(1):103-9. PubMed ID: 9918249
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system vasculitis in children.
Elbers J; Benseler SM
Curr Opin Rheumatol; 2008 Jan; 20(1):47-54. PubMed ID: 18281857
[TBL] [Abstract][Full Text] [Related]
11. The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement.
Lippi G; Franchini M; Targher G; Poli G; Guidi GC
Clin Chim Acta; 2007 Jun; 381(2):167-70. PubMed ID: 17433810
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
13. The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD.
Castaman G; Tosetto A; Goodeve A; Federici AB; Lethagen S; Budde U; Batlle J; Meyer D; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Ingerslev J; Habart D; Hill F; Peake I; Rodeghiero F
Br J Haematol; 2010 Nov; 151(3):245-51. PubMed ID: 20738304
[TBL] [Abstract][Full Text] [Related]
14. Laboratory diagnostic approach of the parents-children relationship in differentiating low-level von Willebrand factor from mild type 1 von Willebrand disease.
Akin M
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):351-3. PubMed ID: 22450546
[TBL] [Abstract][Full Text] [Related]
15. Brain biopsy in children with primary small-vessel central nervous system vasculitis.
Elbers J; Halliday W; Hawkins C; Hutchinson C; Benseler SM
Ann Neurol; 2010 Nov; 68(5):602-10. PubMed ID: 21031577
[TBL] [Abstract][Full Text] [Related]
16. Von Willebrand factor, fibrinogen and other risk factors of thrombosis in patients with a history of cerebrovascular ischemic stroke and their children.
Jastrzebska M; Torbus-Lisiecka B; Honczarenko K; Foltynska A; Chełstowski K; Naruszewicz M
Nutr Metab Cardiovasc Dis; 2002 Jun; 12(3):132-40. PubMed ID: 12325470
[TBL] [Abstract][Full Text] [Related]
17. [Laboratory indicators of endothelial involvement in rheumatic diseases associated with vasculitis in children].
Dolezalová P; Telekesová P; Nĕmcová D; Bĕlorová J; Kvasnicka J; Hoza J
Cas Lek Cesk; 2003; 142(10):615-9. PubMed ID: 14635427
[TBL] [Abstract][Full Text] [Related]
18. von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type I von Willebrand disease--results based on an epidemiological investigation.
Rodeghiero F; Castaman G; Tosetto A
Thromb Haemost; 1990 Nov; 64(3):349-52. PubMed ID: 2096485
[TBL] [Abstract][Full Text] [Related]
19. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
